Game On: Revance Therapeutics Initiates Phase 3 Trial of Topical Botox
Will Revance's RT001 be the first topically neurotoxin treatment?
Will Revance's RT001 be the first topically neurotoxin treatment?
The deal expands Crown’s presence in the aesthetics market, bringing Daxxify and the RHA Collection into its portfolio.
Plastic surgeon Johnny Franco, MD, discusses how his firsthand experience with GLP-1s shaped his patient-centered wellness program and what plastic surgeons should know before adding similar treatments to their aesthetic practices.
Revance Therapeutics Inc, a Newark, Calif-based developer of neuromodulators for the treatment of aesthetic and therapeutic conditions, announces two pieces of company news regarding RT002.
Read MoreJUVEDERM ULTRA XC for lips and Coolscupting’s new Coolmini for the double chin are among November’s “Hot Stuff.”
Read More